• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不可切除的肝细胞癌:经动脉治疗后的磁共振成像。第二部分。经动脉治疗后使用容积功能标准进行反应分层。

Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.

机构信息

Department of Radiology, Johns Hopkins School of Medicine, the Johns Hopkins Hospital, 600 N Wolfe St, MRI 143, Baltimore, MD 21287, USA.

出版信息

Radiology. 2013 Aug;268(2):431-9. doi: 10.1148/radiol.13121637. Epub 2013 Apr 24.

DOI:10.1148/radiol.13121637
PMID:23616632
Abstract

PURPOSE

To assess whether volumetric functional magnetic resonance (MR) results 3-4 weeks after initial intraarterial therapy can aid accurate distinction between responders and nonresponders, to determine whether overall survival (OS) is improved, and to compare volumetric functional MR response with anatomic response criteria (Response Evaluation Criteria in Solid Tumors [RECIST], modified RECIST [mRECIST], European Association for the Study of the Liver [EASL]), as well as α1-fetoprotein [AFP] level.

MATERIALS AND METHODS

In this single-institution HIPAA-compliant retrospective, institutional review board-approved study, informed consent was waived; 143 patients with hepatocellular carcinoma underwent intraarterial therapy between October 2005 and February 2011. Volumetric functional MR response (25% or more increase in apparent diffusion coefficient, 65% or more decrease in enhancement) was stratified as follows: Dual-parameter responders fulfilled both criteria, single-parameter responders fulfilled one criterion, and those with stable disease (SD) fulfilled neither. RECIST, mRECIST, EASL, and AFP response criteria were determined. Kaplan-Meier technique, log-rank tests, and the Cox proportional hazards model were used to test whether OS was different per response.

RESULTS

OS differed significantly between single-parameter responders and dual-parameter responders (P = .01) and between single-parameter responders and those with SD (P = .001). Dual-parameter responders' response improved OS compared with single-parameter responders; risk of death decreased (hazard ratio [HR] = 0.28, P = .01). In those with SD compared with single-parameter responders, risk of death increased (HR = 2.09, P = .001). RECIST, mRECIST, and EASL stratification was short of significant; most lesions were classified as SD. Baseline AFP level increased in 55 patients; AFP responders versus AFP nonresponders had decreased risk of death (HR = 0.36, P = .002). Agreement between anatomic response criteria and volumetric functional MR findings (κ = 0.06-0.12) and between AFP response and imaging criteria (κ = -0.04 to 0.14) was low.

CONCLUSION

Volumetric functional MR response 3-4 weeks after initial intraarterial therapy showed improved OS. Volumetric functional MR was superior to current imaging (RECIST, mRECIST, and EASL) and biochemical (AFP level) response criteria.

摘要

目的

评估初始动脉内治疗后 3-4 周的容积功能磁共振(MR)结果是否有助于准确区分应答者和无应答者,确定总生存率(OS)是否得到改善,并比较容积功能 MR 应答与解剖应答标准(实体瘤反应评估标准[RECIST]、改良 RECIST[mRECIST]、欧洲肝脏研究协会[EASL])以及α1-胎蛋白[AFP]水平。

材料与方法

本研究为机构审查委员会批准的单机构 HIPAA 合规性回顾性研究,豁免了知情同意。2005 年 10 月至 2011 年 2 月,143 例肝细胞癌患者接受了动脉内治疗。容积功能 MR 应答(表观扩散系数增加 25%或以上,增强减少 65%或以上)分为以下几类:双参数应答者满足两个标准,单参数应答者满足一个标准,而疾病稳定(SD)者则不符合任何标准。确定了 RECIST、mRECIST、EASL 和 AFP 应答标准。采用 Kaplan-Meier 技术、对数秩检验和 Cox 比例风险模型来检验 OS 是否因应答而异。

结果

单参数应答者与双参数应答者之间(P=.01)以及单参数应答者与 SD 者之间(P=.001)的 OS 差异具有统计学意义。双参数应答者的反应改善了 OS,与单参数应答者相比,死亡风险降低(风险比[HR] = 0.28,P=.01)。与单参数应答者相比,SD 者的死亡风险增加(HR = 2.09,P=.001)。RECIST、mRECIST 和 EASL 分层不显著;大多数病变被归类为 SD。55 例患者的 AFP 基线水平升高;与 AFP 无应答者相比,AFP 应答者的死亡风险降低(HR = 0.36,P=.002)。解剖应答标准与容积功能 MR 结果之间(κ=0.06-0.12)以及 AFP 应答与成像标准之间(κ=-0.04 至 0.14)的一致性较低。

结论

初始动脉内治疗后 3-4 周的容积功能 MR 反应显示出改善的 OS。容积功能 MR 优于当前的成像(RECIST、mRECIST 和 EASL)和生化(AFP 水平)应答标准。

相似文献

1
Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.不可切除的肝细胞癌:经动脉治疗后的磁共振成像。第二部分。经动脉治疗后使用容积功能标准进行反应分层。
Radiology. 2013 Aug;268(2):431-9. doi: 10.1148/radiol.13121637. Epub 2013 Apr 24.
2
Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.使用三维定量方法对经动脉化疗栓塞治疗的肝细胞癌患者现有疗效标准的比较。
Radiology. 2016 Jan;278(1):275-84. doi: 10.1148/radiol.2015142951. Epub 2015 Jul 1.
3
Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization.胰岛细胞瘤肝转移:经动脉化疗栓塞后功能磁共振成像评估早期容积变化。
Radiology. 2012 Jul;264(1):97-109. doi: 10.1148/radiol.12112161. Epub 2012 May 24.
4
EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.EASL 和 mRECIST 评价索拉非尼联合经动脉化疗栓塞治疗肝细胞癌的疗效反应可预测患者的生存。
Clin Cancer Res. 2014 Mar 15;20(6):1623-31. doi: 10.1158/1078-0432.CCR-13-1716. Epub 2014 Feb 3.
5
Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.经化疗栓塞治疗后肝细胞癌中改良实体瘤反应评估标准与欧洲肝脏研究协会标准的预后价值的前瞻性比较。
Eur J Cancer. 2013 Mar;49(4):826-34. doi: 10.1016/j.ejca.2012.08.022. Epub 2012 Sep 17.
6
Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response.局部区域治疗治疗肝内胆管细胞癌:评估肿瘤反应的定量容积表观扩散系数图。
Radiology. 2012 Jul;264(1):285-94. doi: 10.1148/radiol.12112142. Epub 2012 May 24.
7
Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.肝癌的化疗栓塞治疗:1 个月时的表观扩散系数反应是结局的独立预测因子。
Radiology. 2014 Mar;270(3):747-57. doi: 10.1148/radiol.13130591. Epub 2013 Dec 12.
8
Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.经动脉化疗栓塞术前肝细胞癌分期标志物的识别:三维定量成像标志物与非三维成像标志物的比较
Radiology. 2015 May;275(2):438-47. doi: 10.1148/radiol.14141180. Epub 2014 Dec 19.
9
Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.实体瘤改良反应评估标准和欧洲肝脏研究协会标准在早期时间点使用延迟期成像可预测钇-90放射性栓塞术后不可切除肝内胆管癌患者的生存情况。
J Vasc Interv Radiol. 2014 Feb;25(2):256-65. doi: 10.1016/j.jvir.2013.10.056.
10
Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.评价 mRECIST 和甲胎蛋白比值在索拉非尼治疗的晚期肝细胞癌患者预后分层中的作用。
Oncology. 2012;83(4):192-200. doi: 10.1159/000341347. Epub 2012 Aug 11.

引用本文的文献

1
Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease.测量腰大肌体积在肝病患者肌少症诊断中的应用价值
Diagnostics (Basel). 2023 Mar 26;13(7):1245. doi: 10.3390/diagnostics13071245.
2
Modified quantitative and volumetric response evaluation criteria for patients with hepatocellular carcinoma after transarterial chemoembolization.经动脉化疗栓塞术后肝细胞癌患者改良的定量和容积反应评估标准
Front Oncol. 2023 Jan 25;13:957722. doi: 10.3389/fonc.2023.957722. eCollection 2023.
3
Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?
比较基线成像和载药微球动脉化疗栓塞(lipiodol cTACE)后 HCC 动脉肿瘤血管化:增强肿瘤体积的评估在磁共振成像(MR)和 CT 上有何差异?
Eur Radiol. 2020 Mar;30(3):1601-1608. doi: 10.1007/s00330-019-06430-2. Epub 2019 Dec 6.
4
Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization.基线容积多参数磁共振成像对经动脉化疗栓塞治疗的神经内分泌肝脏转移瘤的预后价值。
Eur Radiol. 2019 Oct;29(10):5160-5171. doi: 10.1007/s00330-019-06100-3. Epub 2019 Mar 15.
5
Functional imaging of hepatocellular carcinoma.肝细胞癌的功能成像
Hepat Oncol. 2016 Apr;3(2):137-153. doi: 10.2217/hep-2015-0005. Epub 2016 Mar 29.
6
How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma.如何评估靶向治疗的疗效或失败:决定肝细胞癌中索拉非尼的停药时机。
World J Hepatol. 2016 Dec 18;8(35):1541-1546. doi: 10.4254/wjh.v8.i35.1541.
7
The Role of Diffusion-Weighted Imaging (DWI) in Locoregional Therapy Outcome Prediction and Response Assessment for Hepatocellular Carcinoma (HCC): The New Era of Functional Imaging Biomarkers.弥散加权成像(DWI)在预测肝细胞癌(HCC)局部区域治疗结果和评估反应中的作用:功能成像生物标志物的新时代。
Diagnostics (Basel). 2015 Nov 30;5(4):546-63. doi: 10.3390/diagnostics5040546.
8
Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).肝细胞癌的新型影像诊断:第五届亚太原发性肝癌专家会议(APPLE 2014)共识
Liver Cancer. 2015 Dec;4(4):215-27. doi: 10.1159/000367742. Epub 2015 Oct 15.
9
Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.使用三维定量方法对经动脉化疗栓塞治疗的肝细胞癌患者现有疗效标准的比较。
Radiology. 2016 Jan;278(1):275-84. doi: 10.1148/radiol.2015142951. Epub 2015 Jul 1.
10
Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.在锥形束CT上对碘油沉积进行术中三维定量可预测肝细胞癌患者经动脉化疗栓塞后的肿瘤反应。
Cardiovasc Intervent Radiol. 2015 Dec;38(6):1548-56. doi: 10.1007/s00270-015-1129-9. Epub 2015 May 23.